

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

NCT07249632

Status	RECRUITING
Phase	Phase 3
Sponsor	RemeGen Co., Ltd.
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (6)

- Voluntarily signed the informed consent form.
- Age 12 to 80 years, inclusive, male or female.
- Body weight \geq 30 kg.
- Diagnosis of Myasthenia Gravis (MG) with documented clinical features consistent with the disease.
- Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Type I.

... and 1 more (see full listing online)

Exclusion (12)

- Concomitant autoimmune diseases requiring systemic corticosteroid therapy.
- Clinically significant laboratory abnormalities.
- Use of other immunosuppressants (not part of the stable SOC) within 1 month prior to randomization.
- Presence of an acute or chronic infection requiring treatment.
- Current active hepatitis or history of severe liver disease.

... and 7 more (see full listing online)

Locations (1 total)

Beijing Hospital, Beijing, Beijing Municipality, China